BioSpace News Archive

In this open-label first stage of a 170-patient study, 20 patients with moderate to severe Crohn’s disease will be treated for up to 52 weeks with the novel investigational agent, QBECO SSI, which is designed to restore, rather than suppress, immune function.

Submission Marks On-time Execution of Second NDA Submission for Tazemetostat in 2019

Achievement marks 15th consecutive year of meeting early certification requirements

Padcev represents a new type of therapy for patients with advanced urothelial cancer whose disease has progressed on chemotherapy and immunotherapy.

The Company has filed the New Drug Application (NDA) for lurbinectedin, in monotherapy, for the treatment of relapsed Small Cell Lung Cancer (SCLC), under the “accelerated approval” regulations.

The Notes are also convertible into Shares at a conversion price of CAD$2.70, CAD$2.72 and CAD$2.82 per Share, respectively, at any time until the Maturity Date.

First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors

Seattle Genetics, Inc. will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM.

Revive Therapeutics Ltd., a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions put forward by the Company at its annual general meeting of shareholders held on December 18, 2019 were approved at the AGM.

Monopar Therapeutics Inc. announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share.